Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 AMG 176 in relapsed or refractory multiple myeloma and acute myeloid leukemia
jRCT2080224749Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of Tapotoclax in multiple myeloma (MM) and acute myeloid leukemia (AML) (8 arms), sponsored by Amgen. Primary endpoints: Safety and tolerability, Pharmacokinetics and 1 more. Started Jun 2019; status: completed.
02
Drugs
Tapotoclax
03
Conditions
multiple myeloma (MM)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080224749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224749.